| bemnifosbuvir (AT-527) / Atea Pharma |
2022-003268-25: A study to evaluate the efficacy and safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19 |
|
|
| Not yet recruiting | 3 | 1500 | Europe | Bemnifosbuvir Hemisulfate, BEM; AT-527, Tablet | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | COVID-19, COVID-19, Diseases [C] - Virus Diseases [C02] | | | | |
NCT05629962: SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19 |
|
|
| Completed | 3 | 2295 | Europe, Canada, Japan, US, RoW | Bemnifosbuvir (BEM), AT-527, Placebo | Atea Pharmaceuticals, Inc. | SARS CoV 2 Infection, COVID-19 | 04/24 | 05/24 | | |
2019-001431-31: A Phase 2 Study Assessing the Safety and Efficacy of AT-527 in Combination with Daclatasvir in Subjects with Chronic HCV Infection |
|
|
| Not yet recruiting | 2 | 15 | Europe | Daklinza, AT-527, na, Tablet, Daklinza | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
| Active, not recruiting | 2 | 275 | Europe, Canada, US, RoW | Bemnifosbuvir, AT-527, Ruzasvir, AT-038 | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C, Hepatic Cirrhosis, HCV | 11/24 | 11/24 | | |
2019-004997-24: A Phase I/IIa Study Assessing AT-777 in Healthy Subjects and AT-777 in Combination with AT-527 in HCV-Infected Subjects |
|
|
| Not yet recruiting | 1/2 | 44 | Europe | AT-527, AT-777, Tablet, Capsule | Atea Pharmaceuticals, Inc., Atea Pharmaceuticals, Inc. | HCV-Infected subjects, Hepatitis C, Diseases [C] - Virus Diseases [C02] | | | | |
| Completed | 1 | 32 | Canada | Cohort 1 BEM + Ruzasvir, AT-527, Cohort 2 Ruzasvir + BEM | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 03/23 | 03/23 | | |
NCT05905497: The Study of Bemnifosbuvir in Healthy Japanese Subjects |
|
|
| Completed | 1 | 14 | US | Bemnifosbuvir (BEM), AT-527 | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/23 | 05/23 | | |
NCT05905484: Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects |
|
|
| Completed | 1 | 35 | Canada | Bemnifosbuvir (BEM), AT-527, Placebo, Moxifloxacin | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/23 | 05/23 | | |
NCT05724693: Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function |
|
|
| Completed | 1 | 39 | US | Bemnifosbuvir (BEM), AT-527 | Atea Pharmaceuticals, Inc. | Healthy Volunteer, Hepatic Impairment | 04/24 | 04/24 | | |
NCT05618314: Study of AT-527 in Subjects With Normal and Impaired Renal Function |
|
|
| Completed | 1 | 36 | Canada | AT-527, Bemnifosbuvir, AT-527 and Probenecid | Atea Pharmaceuticals, Inc. | Healthy Volunteer, Renal Impairment | 06/24 | 06/24 | | |
NCT06204679: Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir |
|
|
| Completed | 1 | 42 | US | Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 08/24 | 08/24 | | |
NCT06356194: Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir |
|
|
| Completed | 1 | 28 | Canada | Cohort 1: Days 1-7 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. Days 8-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 BIK, Cohort 2: Days 1-10 Biktarvy (BIK). Days 11-17 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered + Biktarvy (BIK). Days 18-24 Bemnifosbuvir (BEM)/Ruzasvir (RZR) co-administered. | Atea Pharmaceuticals, Inc. | Healthy Volunteer Study | 05/24 | 05/24 | | |
